New study investigates reasons behind varied responses to PARP inhibitors

28 September 2018

A new study has been published, looking into the reasons why individuals' response to PARP inhibitors can vary.

Comments (0)

Please verify your action

Comment (maximum 3500 characters) (required)

Add a picture

Notify me when someone makes a comment

First name (required)

Last name (required)

Email (required)

Which country do you live in?

Postcode (required)

Address line 1

Address line 2

Town or city

Keeping In Touch

We would love to keep you posted with news, activities and how you can help in other ways. We'll never sell or swap your details with anybody else. You are free to change your mind at any time. Please tick the boxes below to opt in to receive communications from Ovacome by email, SMS, telephone, and/or post.

Via email

Via telephone

Via SMS

Via post

Which country do you live in?

Postcode (required)

Address line 1

Address line 2

Town or city

Your Privacy

We will always store your personal details securely. We'll use them to provide the service that you have requested, and communicate with you in the way(s) that you have agreed to. Your data may also be used for analysis purposes, to help us provide the best service possible. For full details see our Privacy Policy.

By submitting this form you are agreeing to our terms and conditions

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Latest

1st Annual Ovacome Gala: Auction

A list of auction items available for 1st Annual Ovacome Gala in memory of Deborah Baldwin.
Niraparib evaluation by NICE for use in routine commissioning

Niraparib is currently being evaluated by the National Institute for Health and Care Excellence (NICE) for use in routine commissioning – meaning it becomes routinely available on the NHS.
Herefordshire ovarian cancer support group

Come join our new support group in person or online!
Amanda

Amanda was diagnosed with a granulosa cell tumour in early 2020.